文献速递肿瘤 PET/CT核素与放射性配体治疗

18F或177Lu标记的高肿瘤摄取与滞留双价成纤维细胞激活蛋白配体

18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-15

本研究合成双价FAP配体ND-bisFAPI并用18F或177Lu标记,在A549-FAP等荷瘤小鼠中评估PET显像、生物分布与内放射治疗疗效。ND-bisFAPI对FAP亲和力0.25±0.05 nM,比单体DOTA-FAPI-04(IC50=2.0±0.18 nM)高八倍。18F标记物肿瘤摄取与滞留高于[18F]AlF-FAPI-42;177Lu标记物在24、72、120、168小时肿瘤摄取均高于[177Lu]Lu-FAPI-04(均P<0.01),37 MBq治疗显著抑制肿瘤生长。

要点

  • ND-bisFAPI对FAP亲和力为0.25±0.05 nM,比单体DOTA-FAPI-04高八倍
  • 18F标记ND-bisFAPI的肿瘤特异性摄取与滞留高于[18F]AlF-FAPI-42,至少持续6小时
  • 37 MBq [177Lu]Lu-ND-bisFAPI较同剂量[177Lu]Lu-FAPI-04显著抑制A549-FAP肿瘤生长

核心结论

  • 新型双价FAP配体作为诊疗一体化放射性药物,与[18F]AlF-FAPI-42和[177Lu]Lu-FAPI-04相比显示更高的肿瘤摄取与滞留。
  • 18F或177Lu标记ND-bisFAPI的初步实验显示有前景的显像特性与良好的抗肿瘤反应。

研究设计与样本

  • 临床前研究:合成双价FAP配体ND-bisFAPI,用18F或177Lu标记。
  • 体外用FAP阳性A549-FAP细胞研究竞争性结合、细胞内化与外排。
  • 在A549-FAP或U87MG荷瘤小鼠中行[18F]AlF-ND-bisFAPI micro-PET显像。
  • 在A549-FAP荷瘤小鼠中行[177Lu]Lu-ND-bisFAPI生物分布与内放射治疗疗效研究。

主要发现

  • ND-bisFAPI对FAP结合亲和力为0.25±0.05 nM,单体DOTA-FAPI-04的IC50=2.0±0.18 nM,ND-bisFAPI效力高八倍。
  • A549-FAP细胞中ND-bisFAPI显示特异性摄取、高内化比例和缓慢细胞外排。
  • 与单体[18F]AlF-FAPI-42相比,[18F]AlF-ND-bisFAPI micro-PET显示更高的肿瘤特异性摄取与滞留,至少持续6小时。
  • [177Lu]Lu-ND-bisFAPI在24、72、120、168小时时间点肿瘤摄取均高于[177Lu]Lu-FAPI-04(均P<0.01)。
  • [177Lu]Lu-ND-bisFAPI向A549-FAP肿瘤递送的辐射量为[177Lu]Lu-FAPI-04的四倍。

关键数值与推荐

  • ND-bisFAPI的FAP结合亲和力为0.25±0.05 nM;单体DOTA-FAPI-04的IC50=2.0±0.18 nM。
  • [177Lu]Lu-ND-bisFAPI在24、72、120、168小时的肿瘤摄取均高于[177Lu]Lu-FAPI-04(均P<0.01)。
  • 37 MBq [177Lu]Lu-ND-bisFAPI较同剂量[177Lu]Lu-FAPI-04显著降低肿瘤生长。
  • 18.5 MBq [177Lu]Lu-ND-bisFAPI与37 MBq [177Lu]Lu-FAPI-04中位生存期分别为37天与36天。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论称上述为初步实验(Preliminary experiments),显示有前景的显像特性与良好的抗肿瘤反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fibroblast activation protein (FAP) has become a promising cancer-related target for diagnosis and therapy. The aim of this study was to develop a bivalent FAP ligand for both diagnostic PET imaging and endoradiotherapy. METHODS: We synthesized a bivalent FAP ligand (ND-bisFAP) and labeled it with 18F or 177Lu. FAP-positive A549-FAP cells were used to study competitive binding to FAP, cellular internalization, and efflux properties in vitro. Micro-PET imaging with [18F]AlF-ND-bisFAPI was conducted in mice bearing A549-FAP or U87MG tumors. Biodistribution and therapeutic efficacy of [177Lu]Lu-ND-bisFAPI were conducted in mice bearing A549-FAP tumors. RESULTS: The FAP binding affinity of ND-bisFAPI is 0.25 ± 0.05 nM, eightfold higher in potency than the monomeric DOTA-FAPI-04 (IC50 = 2.0 ± 0.18 nM). In A549-FAP cells, ND-bisFAPI showed specific uptake, a high internalized fraction, and slow cellular efflux. Compared to the monomeric [18F]AlF-FAPI-42, micro-PET imaging with [18F]AlF-ND-bisFAPI showed higher specific tumor uptake and retention for at least 6 h. Biodistribution studies showed that [177Lu]Lu-ND-bisFAPI had higher tumor uptake than [177Lu]Lu-FAPI-04 at the 24, 72, 120, and 168 h time points (all P < 0.01). [177Lu]Lu-ND-bisFAPI delivered fourfold higher radiation than [177Lu]Lu-FAPI-04 to A549-FAP tumors. For the endoradiotherapy study, 37 MBq of [177Lu]Lu-ND-bisFAPI significantly reduced tumor growth compared to the same dose of [177Lu]Lu-FAPI-04. Half of the dose of [177Lu]Lu-ND-bisFAPI (18.5 MBq) has comparable median survival as 37 MBq of [177Lu]Lu-FAPI-04 (37 vs 36 days). CONCLUSION: The novel bivalent FAP ligand was developed as a theranostic radiopharmaceutical and showed promising properties including higher tumor uptake and retention compared to the established radioligands [18F]AlF-FAPI-42 and [177Lu]Lu-FAPI-04. Preliminary experiments with 18F- or 177Lu-labeled ND-bisFAPI showed promising imaging properties and favorable anti-tumor responses.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li H, Ye S, Li Li, et al. 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022. PMID: 35290473. doi:10.1007/s00259-022-05757-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。